Financial Overview - The total assets of the company at the end of the reporting period amounted to CNY 2,320,746,040.93, an increase from CNY 2,290,524,143.62 at the beginning of the period, reflecting a growth of approximately 1.32% [1][2][3] - Total liabilities decreased from CNY 776,415,444.06 to CNY 724,223,054.96, representing a decline of about 6.71% [2][3] - The total equity increased from CNY 1,514,108,699.56 to CNY 1,596,522,985.97, indicating a growth of approximately 5.46% [2][3] Revenue and Profitability - The total operating revenue for the first half of 2025 was CNY 957,309,406.16, down from CNY 1,008,128,208.10 in the same period of 2024, marking a decrease of about 5.04% [3][4] - Total operating costs decreased from CNY 897,060,160.66 to CNY 837,453,429.08, a reduction of approximately 6.65% [3][4] - The net profit for the first half of 2025 was CNY 100,293,909.16, compared to CNY 86,792,633.13 in the previous year, reflecting an increase of about 15.25% [4][5] Cash Flow - The net cash flow from operating activities was CNY 23,107,715.29, a decrease from CNY 51,569,414.20 in the previous year [6][7] - Cash and cash equivalents at the end of the period were CNY 562,916,068.85, down from CNY 586,430,669.66 at the beginning of the period [6][7] Expenses - Selling expenses decreased significantly from CNY 121,398,899.05 to CNY 66,029,184.50, a reduction of approximately 45.49% [4][5] - Research and development expenses increased from CNY 9,226,381.24 to CNY 11,833,550.53, reflecting a growth of about 28.38% [4][5] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 were CNY 0.1683, up from CNY 0.1457 in the same period of 2024, indicating an increase of approximately 15.93% [4][5]

证券代码：000788 证券简称：北大医药 公告编号：2025-059 北大医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 一届董事会第十三次会议、第十一届监事会第八次会议分别审议通过了《关于修 订 <公司章程> 及相关附件的议案》。根据中国证券监督管理委员会发布的《关于 新 <公司法> 配套制度规则实施相关过渡期安排》《上市公司章程指引》等相关法 律法规的规定，为进一步规范公司运作，结合公司实际情况, 公司拟调整治理结 构，不再设置监事会，监事会的职权由董事会审计委员会行使，公司《监事会议 事规则》等监事会相关制度相应废止。据此，公司拟对《公司章程》及其附件《股 东大会议事规则》《董事会议事规则》进行修订，具体如下： 一、《公司章程》修订情况 和《上市公司章程指引》等相关法律法规规定，公司不再设置监事会。《公司章 程》中对涉及"监事"、"监事会"的条款进行修订，删除"监事"、"监事会" 相关描述，涉及监事会或监事职权行使的表述修改为由审计委员会或审计委员会 ...

Summary of Key Points Core Viewpoint - The report outlines the non-operating fund occupation and other related fund transactions of Beijing University Medical Corporation, highlighting significant amounts involved in accounts receivable and other receivables with various related parties, primarily under the control of China Ping An and New Fangzheng Group. Group 1: Non-Operating Fund Occupation - The total amount of non-operating fund occupation reached 115,452.15 million RMB, with a cumulative amount of 50,880.77 million RMB as of the end of June 2025 [5] - The report specifies that the funds are primarily occupied by related parties, including subsidiaries and affiliates of the controlling shareholders [5] Group 2: Accounts Receivable - Accounts receivable from related parties include significant amounts such as 70,675.54 million RMB from Beijing University International Hospital and 1,795.94 million RMB from Hunan Kaide Micro-Creative Hospital [2][3] - The report indicates that these accounts receivable are primarily due to sales of goods and are categorized as operational transactions [2][3] Group 3: Other Receivables - Other receivables include amounts such as 30.25 million RMB for rental deposits and 2.34 million RMB for other operational transactions related to Beijing University International Hospital [3] - The report also notes that there are significant prepayments, including 33.20 million RMB for rent and 21.48 million RMB for insurance [3] Group 4: Shareholder Changes - The report mentions a significant change in the controlling shareholder, with New Fangzheng Group transferring its 100% stake in Southwest Synthesis Pharmaceutical Group to New Advantage International, effective December 23, 2024 [5] - This change will result in a new actual controller, Xu Xiren, taking over the management of the company [5]

Core Viewpoint - The company has agreed to cooperate with its investee company, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., in reducing its registered capital and initiating liquidation due to severe operational difficulties [1][2][4]. Summary by Sections Basic Situation Overview - The investee company has a registered capital of 300 million RMB, with the company holding a 41% stake, amounting to an investment of 41 million RMB [1][2]. - The registered capital will be reduced from 300 million RMB to 100 million RMB, maintaining the proportionate contributions of all shareholders [2][5]. Approval Process - The board of directors approved the proposal with a unanimous vote of 3 in favor, 0 against, and 0 abstentions [3][4]. - The supervisory board also approved the proposal with a unanimous vote of 5 in favor, 0 against, and 0 abstentions [5]. Impact on the Company - The reduction of capital and subsequent liquidation of the investee company is aimed at optimizing the company's investment layout and reducing operational risks, which is expected to protect the interests of all shareholders, including minority shareholders [4][5]. - The actions taken will not have a substantial impact on the company's overall business development and profitability [5].

北大医药股份有限公司董事会议事规则 （2025 年 8 月修正案） 北大医药股份有限公司（以下简称"公司"）董事会是公司股东会的常设机 构，在股东会闭会期间行使股东会授予的职权，为了保障董事会依法行使职权， 确保董事会工作的正常秩序和议事效率，根据《中华人民共和国公司法》（以下 简称《公司法》） 《中华人民共和国证券法》 （以下简称《证券法》）等法律、法规 和规范性文件以及《北大医药股份有限公司章程》 （以下简称《公司章程》）的规 定，制定本规则。 人士），设董事长 1 名。 第三条 董事会行使以下职权： （一）负责召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的年度财务预算方案、决算方案； （五）制订公司的利润分配方案和弥补亏损方案； （六）制订公司增加或者减少注册资本、发行债券或其他证券及上市方案； （七）拟订公司重大收购、回购本公司股票或者合并、分立和解散方案； 第一条 公司设董事会，董事会对股东会负责。 第二条 董事会由 9 名董事组成，其中独立董事 3 名（其中一人为会计专业 （八）在股东会授权范围内，决定公司对外投资、收购出售资产、 ...

北大医药股份有限公司 公司章程 （二〇二五年八月修订） 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国 证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 公司系依照《股份有限公司规范意见》和其他有关规定于1993年4月经 重庆市体改委[1993]91号文批准而设立的定向募集股份有限公司。公司在重庆市市 场监督管理局注册登记，取得营业执照，统一社会信用代码91500000450533779H。 司，并依法履行了重新登记手续。 第三条 公司于1997年5月15日经中国证券监督管理委员会批准，首次向社会公 众发行人民币普通股4500万股。其中，向职工发行的以人民币认购的职工股450万股， 并已分别于1997年6月16日和1997年12月18日在深圳证券交易所上市。 第四条 公司注册名称： 中文全称: 北大医药股份有限公司 英文全称：PKU HealthCare Corp., Ltd. 第五条 公司住所：重庆市北碚区水土镇方正大道21号。 邮政编码：400714 第六条 公司注册资本为人民币 ...

Core Viewpoint - The report highlights the financial performance and operational strategies of Peking University Health Science Center Co., Ltd. for the first half of 2025, indicating a decline in revenue but an increase in net profit, driven by improved product profitability and cost control measures [1][7]. Company Overview and Financial Indicators - The company reported a revenue of CNY 957.31 million, a decrease of 5.04% compared to the previous year [2][7]. - The net profit attributable to shareholders was CNY 100.29 million, reflecting a growth of 15.51% year-on-year [2][7]. - The basic earnings per share increased to CNY 0.1683, up 15.51% from the previous year [2][7]. - Total assets at the end of the reporting period were CNY 2.32 billion, a 1.32% increase from the end of the previous year [2][7]. - The net assets attributable to shareholders rose by 5.44% to CNY 1.60 billion [2][7]. Industry Context - The pharmaceutical manufacturing industry faced a revenue decline of 1.2% year-on-year, with total profits down 2.8%, indicating pressure on revenue and profitability due to market competition and cost control [6][7]. - The industry is undergoing significant transformation, shifting from scale expansion to quality-driven development, particularly influenced by advancements in technologies such as artificial intelligence and gene editing [6][7]. Business Operations - The company primarily engages in the research, production, and sales of chemical drug formulations, pharmaceutical distribution, and medical services [6][7]. - The main therapeutic areas include anti-infective, analgesic, and psychiatric medications, with a focus on enhancing product reserves and improving product profitability [6][7]. - The company has established a comprehensive marketing network and is exploring innovative cooperation models to expand its market presence [6][8]. Financial Performance Analysis - The company's operating costs decreased by 0.95% to CNY 710.06 million, attributed to changes in product sales structure and pricing strategies [11]. - Research and development expenses increased by 28.26% to CNY 11.83 million, reflecting a commitment to innovation and product development [12]. - The company successfully completed the consistency evaluation for key products, demonstrating its R&D capabilities and commitment to quality improvement [7][8]. Strategic Initiatives - The company aims to deepen its strategic layout by focusing on integrated raw material and formulation development, enhancing brand building, and fostering cultural integration [10][11]. - A strategic partnership with a major retail pharmacy chain in Southwest China was established to explore innovative marketing models and enhance service delivery to retail patients [8][10].

北大医药股份有限公司 2025 年半年度报告摘要 证券代码：000788 证券简称：北大医药 公告编号：2025-060 北大医药股份有限公司 2025 年半年度报告摘要 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监 会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 ?不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 ?适用 □不适用 是否以公积金转增股本 □是 ?否 公司经本次董事会审议通过的利润分配预案为：以 595,987,425 股为基数，向全体股东每 10 股派发现 金红利 0.30 元 （含税），送红股 0 股（含税） ，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 ?不适用 二、公司基本情况 股票简称 北大医药 股票代码 000788 股票上市交易所 深圳证券交易所 联系人和联系方式 董事会秘书 证券事务代表 姓名 袁宇飞 何苗 办公地址 重庆市渝北区金开大道 56 号两江天地 1 单元 10 楼 重庆市渝北区金开大道 56 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-057 北大医药股份有限公司 关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 北大医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 一届董事会第十三次会议，以 8 票同意，0 票反对，0 票回避，0 票弃权的表决 结果审议通过了《2025 年半年度利润分配预案》。 公司于 2025 年 8 月 20 日召开第十一届监事会第八次会议，以 5 票同意，0 票反对，0 票回避，0 票弃权的表决结果审议通过了《2025 年半年度利润分配预 案》。 公司独立董事于 2025 年 8 月 19 日召开第十一届董事会独立董事专门会议第 七次会议，以 3 票同意，0 票反对，0 票弃权的表决结果审议通过了《2025 年半 年度利润分配预案》。 公司独立董事核查后认为，公司 2025 年半年度利润分配预案综合考虑了公 司发展战略、盈利前景、未来资金使用需求、资产状况、市场环境等因素，与公 司业绩成长性相匹配，符合公司实际情况，兼 ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，北大医药发布公告称，公司第十一届董事会第十三次会议审议通过了 《2025年半年度报告全文及摘要》等多项议案。 ...